Waste disposal - An attractive strategy for cancer therapy

Science

Volumn 355, Issue 6330, 2017, Pages 1163-1167

  Salami, Jemilat ^a   Crews, Craig M ^a,b  

^a YALE UNIVERSITY   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 CHLOROPHENYL) 2,3,9 TRIMETHYL 6H THIENO[3,2 F][1,2,4]TRIAZOLO[4,3 A][1,4]DIAZEPINE 6 ACETIC ACID TERT BUTYL ESTER; ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; BIRABRESIB; CANERTINIB; ENZALUTAMIDE; ERLOTINIB; FULVESTRANT; IMATINIB; LENALIDOMIDE; OLAPARIB; PALBOCICLIB; POMALIDOMIDE; PROTEASOME; PROTEIN; RETINOIC ACID; TAMOXIFEN; UBIQUITIN; UBIQUITIN PROTEIN LIGASE E3; ENZYME INHIBITOR; MOLECULAR LIBRARY; MORPHOLINE DERIVATIVE; PROTEIN TYROSINE KINASE;

ANTIBODY; CANCER; CELLS AND CELL COMPONENTS; DEGRADATION; ENZYME ACTIVITY; PROTEIN; QUALITY CONTROL; WASTE DISPOSAL;

ANTINEOPLASTIC ACTIVITY; BIOTECHNOLOGY; CANCER CELL CULTURE; CANCER PATIENT; CELL PROLIFERATION; CHIMERA; HUMAN; MALIGNANT NEOPLASM; MOLECULARLY TARGETED THERAPY; MOLECULE; NONHUMAN; PHARMACOLOGY; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROSTATE CANCER CELL LINE; PROTEIN DEGRADATION; PROTEIN TARGETING; QUALITY CONTROL; REVIEW; SIGNAL TRANSDUCTION; UBIQUITINATION; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG EFFECTS; ENZYMOLOGY; METABOLISM; MOLECULAR LIBRARY; NEOPLASMS; THERAPEUTIC USE;

ANTINEOPLASTIC AGENTS; ENZYME INHIBITORS; HUMANS; MOLECULAR TARGETED THERAPY; MORPHOLINES; NEOPLASMS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN-TYROSINE KINASES; PROTEOLYSIS; SMALL MOLECULE LIBRARIES; UBIQUITIN;

EID: 85015298100     PISSN: 00368075     EISSN: 10959203     Source Type: Journal    
DOI: 10.1126/science.aam7340     Document Type: Review

References (49)

1. J. Ferlay et al., Int. J. Cancer 136, E359-E386 (2015).
2. B. A. Teicher, J. E. Tomaszewski, Biochem. Pharmacol. 96, 1-9 (2015).
3. X. Huang, V. M. Dixit, Cell Res. 26, 484-498 (2016).
4. D. Chauhan et al., Cancer Cell 22, 345-358 (2012).
5. D. S. Johnson, E. Weerapana, B. F. Cravatt, Future Med. Chem. 2, 949-964 (2010).
6. Y. Ye, M. Rape, Nat. Rev. Mol. Cell Biol. 10, 755-764 (2009).
7. R. J. Deshaies, C. A. P. Joazeiro, Annu. Rev. Biochem. 78, 399-434 (2009).
8. J. R. Skaar, J. K. Pagan, M. Pagano, Nat. Rev. Drug Discov. 13, 889-903 (2014).
9. A. Citri et al., EMBO J. 21, 2407-2417 (2002).
10. A. Howell, Endocr. Relat. Cancer 13, 689-706 (2006).
11. T.-D. Zhang et al., Oncogene 20, 7146-7153 (2001).
12. J. Krönke et al., Nature 523, 183-188 (2015).
13. J. Krönke et al., Science 343, 301-305 (2014).
14. L. Mi et al., J. Biol. Chem. 284, 17039-17051 (2009).
15. A. Bill et al., J. Biol. Chem. 289, 11029-11041 (2014).
16. K. M. Sakamoto et al., Proc. Natl. Acad. Sci. U.S.A. 98, 8554-8559 (2001).
17. K. M. Sakamoto et al., Mol. Cell. Proteomics 2, 1350-1358 (2003).
18. A. Howell, S. J. Howell, D. G. Evans, Cancer Chemother. Pharmacol. 52 (suppl. 1), 39-44 (2003).
19. Y. Zhou, E. C. Bolton, J. O. Jones, J. Mol. Endocrinol. 54, R15-R29 (2015).
20. K. Cyrus, M. Wehenkel, E.-Y. Choi, H. Swanson, K.-B. Kim, ChemBioChem 11, 1531-1534 (2010).
21. A. R. Schneekloth, M. Pucheault, H. S. Tae, C. M. Crews, Bioorg. Med. Chem. Lett. 18, 5904-5908 (2008).
22. D. L. Buckley et al., Angew. Chem. Int. Ed. 51, 11463-11467 (2012).
23. D. P. Bondeson et al., Nat. Chem. Biol. 11, 611-617 (2015).
24. A. Lopez-Girona et al., Leukemia 26, 2326-2335 (2012).
25. K. Sekine et al., J. Biol. Chem. 283, 8961-8968 (2008).
26. A. C. Lai et al., Angew. Chem. Int. Ed. 55, 807-810 (2016).
27. Y. Itoh, M. Ishikawa, M. Naito, Y. Hashimoto, J. Am. Chem. Soc. 132, 5820-5826 (2010).
28. K. Okuhira et al., Cancer Sci. 104, 1492-1498 (2013).
29. H. Lebraud, D. J. Wright, C. N. Johnson, T. D. Heightman, ACS Cent. Sci. 2, 927-934 (2016).
30. T. K. Neklesa et al., Nat. Chem. Biol. 7, 538-543 (2011).
31. T. Xie et al., Nat. Chem. Biol. 10, 1006-1012 (2014).
32. J. L. Gustafson et al., Angew. Chem. Int. Ed. 54, 9659-9662 (2015).
33. K. Raina et al., Proc. Natl. Acad. Sci. U.S.A. 113, 7124-7129 (2016).
34. A. C. Belkina, G. V. Denis, Nat. Rev. Cancer 12, 465-477 (2012).
35. I. A. Asangani et al., Nature 510, 278-282 (2014).
36. J. E. Delmore et al., Cell 146, 904-917 (2011).
37. C. A. French et al., Oncogene 27, 2237-2242 (2008).
38. M. G. Baratta et al., Proc. Natl. Acad. Sci. U.S.A. 112, 232-237 (2015).
39. J. A. Mertz et al., Proc. Natl. Acad. Sci. U.S.A. 108, 16669-16674 (2011).
40. Z. Cheng et al., Clin. Cancer Res. 19, 1748-1759 (2013).
41. R. K. Prinjha, J. Witherington, K. Lee, Trends Pharmacol. Sci. 33, 146-153 (2012).
42. J. Lu et al., Chem. Biol. 22, 755-763 (2015).
43. G. E. Winter et al., Science 348, 1376-1381 (2015).
44. M. Zengerle, K. H. Chan, A. Ciulli, ACS Chem. Biol. 10, 1770-1777 (2015).
45. A. P. Russ, S. Lampel, Drug Discov. Today 10, 1607-1610 (2005).
46. D. L. Wheeler et al., Oncogene 27, 3944-3956 (2008).
47. F. Garner, M. Shomali, D. Paquin, C. R. Lyttle, G. Hattersley, Anticancer Drugs 26, 948-956 (2015).
48. C. Tovar et al., Cancer Res. 73, 2587-2597 (2013).
49. M. Korpal et al., Cancer Discov. 3, 1030-1043 (2013).